Division of Nephrology, Department of Internal Medicine, Yeungnam University Medical Center, Yeungnam University College of Medicine, Daegu, Korea
Copyright © 2020 Yeungnam University College of Medicine
This is an Open Access article distributed under the terms of the Creative Commons Attribution Non-Commercial License (http://creativecommons.org/licenses/by-nc/4.0/) which permits unrestricted non-commercial use, distribution, and reproduction in any medium, provided the original work is properly cited.
Variable | Phase I | Phase II | p-value |
---|---|---|---|
No. of patients | 260 | 300 | - |
Underlying disease of ESRD (DM) | 123 (47.3) | 144 (48.0) | 0.870 |
No. of catheterizations | 364 | 367 | - |
Age (yr) | 64.0±15.5 | 63.8±14.3 | 0.837 |
Male sex | 143 (55.0) | 177 (59.0) | 0.340 |
Hemoglobin (g/dL) | 9.6±1.8 | 9.8±1.9 | 0.216 |
Platelet (K/mm3) | 206±131 | 198±126 | 0.473 |
Calcium (mg/dL) | 7.7±1.2 | 7.5±1.0 | 0.297 |
Phosphorus (mg/dL) | 5.1±2.3 | 5.3±1.9 | 0.453 |
Aspartate aminotransferase (IU/L) | 215±817 | 200±496 | 0.829 |
Alanine aminotransferase (IU/L) | 102±317 | 103±252 | 0.987 |
Blood urea nitrogen (mg/dL) | 69.7±39.0 | 65.0±39.6 | 0.186 |
Creatinine (mg/dL) | 6.0±3.8 | 5.8±3.8 | 0.589 |
Sodium (mEq/L) | 135.2±6.4 | 136.9±6.7 | 0.002 |
Potassium (mEq/L) | 4.4±1.0 | 4.2±0.9 | 0.206 |
Continuous renal replacement therapy | 41 (15.8) | 46 (15.3) | 0.887 |
Type of hemodialysis catheter | <0.001 | ||
Non-TCC (FV) | 176 (48.4) | 171 (46.6) | |
Non-TCC (IJV) | 188 (51.6) | 76 (20.7) | |
TCC (IJV) | 0 | 120 (32.7) |
Variable | Unadjusted | Adjusted | ||
---|---|---|---|---|
HR (95% CI) | p-value | HR (95% CI) | p-value | |
Age (ref: ≤65 yr) | 1.30 (0.96–1.77) | 0.096 | 1.03 (0.71–1.47) | 0.895 |
Comorbidities (ref: non-DM) | 1.31 (0.96–1.79) | 0.085 | 1.28 (0.88–1.85) | 0.199 |
Serum sodium (increase 1 unit) | 1.00 (0.97–1.03) | 0.872 | 1.00 (0.97–1.03) | 0.979 |
Phase II (ref: phase I) | 0.70 (0.51–0.96) | 0.024 | 0.55 (0.37–0.79) | 0.002 |
Variable | Phase I (n=97) | Phase II (n=68) | p-value |
---|---|---|---|
Age<65 yr | 41 (17.6) | 30 (17.6) | 0.120 |
Age≥65 yr | 56 (28.6) | 38 (19.3) | 0.033 |
Non-diabetes mellitus | 57 (28.8) | 38 (20.1) | 0.047 |
Diabetes mellitus | 40 (24.1) | 30 (16.9) | 0.095 |
Male sex | 56 (27.9) | 37 (17.1) | 0.008 |
Female sex | 41 (25.2) | 31 (20.7) | 0.346 |
Variable | Unadjusted | Adjusted | ||
---|---|---|---|---|
HR (95% CI) | p-value | HR (95% CI) | p-value | |
Age<65 yr | ||||
Sex (ref: male) | 1.26 (0.77–1.95) | 0.392 | 1.23 (0.72–2.11) | 0.443 |
Comorbidity (ref: non-DM) | 1.81 (1.13–2.91) | 0.014 | 1.73 (1.02–2.93) | 0.043 |
Serum sodium (increase 1 unit) | 1.00 (0.96–1.04) | 0.911 | 1.00 (0.96–1.05) | 0.927 |
Phase II (ref: phase I) | 0.71 (0.44–1.13) | 0.144 | 0.65 (0.37–1.12) | 0.122 |
Age≥65 yr | ||||
Sex (ref: male) | 0.84 (0.55–1.27) | 0.402 | 1.00 (0.59–1.68) | 0.998 |
Comorbidity (ref: non-DM) | 1.01 (0.67–1.53) | 0.947 | 0.96 (0.57–1.62) | 0.885 |
Serum sodium (increase 1 unit) | 1.00 (0.96–1.03) | 0.863 | 1.00 (0.97–1.04) | 0.922 |
Phase II (ref: phase I) | 0.70 (0.46–1.07) | 0.097 | 0.49 (0.29–0.83) | 0.008 |
Non-DM | ||||
Sex (ref: male) | 0.85 (0.56–1.29) | 0.452 | 0.95 (0.59–1.56) | 0.850 |
Age (ref: ≤65 yr) | 0.98 (0.65–1.47) | 0.916 | 0.76 (0.48–1.23) | 0.268 |
Serum sodium (increase 1 unit) | 0.98 (0.95–1.02) | 0.346 | 0.99 (0.95–1.02) | 0.508 |
Phase II (ref: phase I) | 0.83 (0.55–1.25) | 0.369 | 0.68 (0.41–1.11) | 0.125 |
DM | ||||
Sex (ref: male) | 1.26 (0.79–2.02) | 0.332 | 1.24 (0.71–2.19) | 0.450 |
Age (ref: ≤65 yr) | 1.79 (1.11–2.89) | 0.017 | 1.44 (0.82–2.52) | 0.207 |
Serum sodium (increase 1 unit) | 1.02 (0.98–1.07) | 0.406 | 1.03 (0.98–1.08) | 0.241 |
Phase II (ref: phase I) | 0.60 (0.37–0.96) | 0.033 | 0.42 (0.23–0.75) | 0.003 |
Male sex | ||||
Age (ref: ≤65 yr) | 1.53 (1.01–2.31) | 0.044 | 1.02 (0.63–1.66) | 0.938 |
Comorbidity (ref: non-DM) | 1.54 (1.01–2.34) | 0.044 | 1.43 (0.86–2.37) | 0.167 |
Serum sodium (increase 1 unit) | 0.99 (0.95–1.02) | 0.460 | 0.99 (0.95–1.02) | 0.525 |
Phase II (ref: phase I) | 0.58 (0.38–0.88) | 0.011 | 0.47 (0.28–0.78) | 0.003 |
Female sex | ||||
Age (ref: ≤65 yr) | 1.05 (0.66–1.68) | 0.830 | 0.84 (0.47–1.49) | 0.551 |
Comorbidity (ref: non-DM) | 1.06 (0.67–1.69) | 0.799 | 1.12 (0.64–1.94) | 0.701 |
Serum sodium (increase 1 unit) | 1.01 (0.97–1.06) | 0.567 | 1.02 (0.97–1.06) | 0.476 |
Phase II (ref: phase I) | 0.88 (0.55–1.41) | 0.594 | 0.72 (0.40–1.30) | 0.273 |
Values are presented as mean±standard deviation or number (%). ESRD, end-stage renal disease; DM, diabetes mellitus; TCC, tunneled cuffed catheter; FV, femoral vein; IJV, internal jugular vein. Statistical significances were determined using the
The multivariate analysis was adjusted for age, DM, serum sodium level, and phase. HR, hazard ratio; CI, confidence interval; DM, diabetes mellitus.
Values are presented as number (%). Significant differences between phases were determined using Pearson chi-square test.
The multivariate analysis was adjusted for DM, sex, serum sodium level, and phase for the age subgroup; for age, sex, serum sodium level, and phase for the DM subgroup; and for age, DM, serum sodium level, and phase for the sex subgroup. HR, hazard ratio; CI, confidence interval; DM, diabetes mellitus.